Clinicopathological and immunohistochemical evaluation of lonidamine-entrapped lipid-polymer hybrid nanoparticles in treatment of benign prostatic hyperplasia: An experimental rat model

Basit Öğe Kaydı
dc.contributor.authorSengel-Turk, Ceyda Tuba
dc.contributor.authorAlcigir, Mehmet Eray
dc.contributor.authorEkim, Okan
dc.contributor.authorBakar-Ates, Filiz
dc.contributor.authorHascicek, Canan
dc.date.accessioned2021-01-14T18:10:20Z
dc.date.available2021-01-14T18:10:20Z
dc.date.issued2020
dc.departmentKKÜ
dc.descriptionBakar-Ates, Filiz/0000-0003-2809-8946
dc.description.abstractBenign prostatic hyperplasia (BPH) is a progressive proliferative disease, the incidence of which is constantly increasing due to aging of population. In this research, a hexokinase-II enzyme inhibiting agent, lonidamine - the use of which is limited in BPH treatment due to high hepatic toxicity observed after three months of treatment - was selected as an active agent, based on its mechanism of action in treating BPH. The aim of this study was to evaluate in vivo therapeutic efficacy and hepatic toxicity of lipid-polymer hybrid nanoparticles of lonidamine in a rat BPH model created in rat prostates. After local injections of hybrid nanoparticles of lonidamine were administered to the rat prostates, hyperplasic structures of prostates were evaluated in terms of prostatic index values, immunohistochemical evaluations, and histopathological findings. Liver blood enzyme values were also determined to specify hepatic toxicity. Apoptosis was evaluated by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) reaction and histopathological methods to determine intravital degenerative destruction in liver. Through this study, lonidamine-loaded hybrid nanoparticles were found to reduce the he-patic toxicity and increase therapeutic efficiency of lonidamine. Therefore, lonidamine-entrapped hybrid nanoparticles may provide a promising, and very safe, drug delivery strategy in the treatment of BPH.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [114S132]en_US
dc.description.sponsorshipThis work was supported by the Scientific and Technological Research Council of Turkey (TUBITAK), Grant No: 114S132.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1016/j.ejpb.2020.10.016
dc.identifier.endpage220en_US
dc.identifier.issn0939-6411
dc.identifier.issn1873-3441
dc.identifier.pmid33129926
dc.identifier.scopus2-s2.0-85094590983
dc.identifier.scopusqualityQ1
dc.identifier.startpage211en_US
dc.identifier.urihttps://doi.org/10.1016/j.ejpb.2020.10.016
dc.identifier.urihttps://hdl.handle.net/20.500.12587/12510
dc.identifier.volume157en_US
dc.identifier.wosWOS:000591437800003
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherELSEVIERen_US
dc.relation.ispartofEUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLipid-polymer hybrid nanoparticlesen_US
dc.subjectBenign prostatic hyperplasiaen_US
dc.subjectLonidamineen_US
dc.subjectLocal treatmenten_US
dc.subjectHepatic toxicityen_US
dc.titleClinicopathological and immunohistochemical evaluation of lonidamine-entrapped lipid-polymer hybrid nanoparticles in treatment of benign prostatic hyperplasia: An experimental rat modelen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Clinicopathological and immunohistochemical evaluation of lonidamine-entrapped lipid-polymer hybrid nanoparticles in treatment of benign prostatic hyperplasia.pdf
Boyut:
8.56 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu